Rituximab for the treatment of rheumatoid arthritis: an update

References

• McInnes IB Schett G The pathogenesis of rheumatoid arthritis N Engl J Med 2011 365 23 2205 2219 22150039
   PubMed Web of Science ®Google Scholar
• Fox DA Gizinski A Morgan R Lundy SK Cell-cell interactions in rheumatoid arthritis synovium Rheum Dis Clin North Am 2010 36 2 311 323 20510236
   PubMed Web of Science ®Google Scholar
• Choy E Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis Rheumatology (Oxford) 2012 51 Suppl 5 v3 v11 22718924
   PubMed Web of Science ®Google Scholar
• Klareskog L Malmström V Lundberg K Padyukov L Alfredsson L Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis Semin Immunol 2011 23 2 92 98 21376627
   PubMed Web of Science ®Google Scholar
• Scher JU B-cell therapies for rheumatoid arthritis Bull NYU Hosp Jt Dis 2012 70 3 200 203 23259629
   PubMedGoogle Scholar
• Panayi GS B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford) 2005 44 Suppl 2 ii3 ii7 15851524
   PubMed Web of Science ®Google Scholar
• Takemura S Klimiuk PA Braun A Goronzy JJ Weyand CM T cell activation in rheumatoid synovium is B cell dependent J Immunol 2001 167 8 4710 4718 11591802
   PubMed Web of Science ®Google Scholar
• Roosnek E Lanzavecchia A Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells J Exp Med 1991 173 2 487 489 1703209
   PubMed Web of Science ®Google Scholar
• Marston B Palanichamy A Anolik JH B cells in the pathogenesis and treatment of rheumatoid arthritis Curr Opin Rheumatol 2010 22 3 307 315 20090526
   PubMed Web of Science ®Google Scholar
• Kaser A Dunzendorfer S Offner FA B lymphocyte-derived IL-16 attracts dendritic cells and Th cells J Immunol 2000 165 5 2474 2480 10946273
   PubMed Web of Science ®Google Scholar
• Edwards JC Cambridge G Abrahams VM Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999 97 2 188 196 10447731
   PubMed Web of Science ®Google Scholar
• Corsiero E Bombardieri M Manzo A Bugatti S Uguccioni M Pitzalis C Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases Immunol Lett 2012 145 1–2 62 67 22698185
   PubMed Web of Science ®Google Scholar
• Rosengren S Wei N Kalunian KC Kavanaugh A Boyle DL CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis Rheumatology (Oxford) 2011 50 3 603 610 21098574
   PubMed Web of Science ®Google Scholar
• Leandro MJ Becerra-Fernandez E B-cell therapies in established rheumatoid arthritis Best Pract Res Clin Rheumatol 2011 25 4 535 548 22137923
   PubMed Web of Science ®Google Scholar
• Pescovitz MD Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action Am J Transplant 2006 6 5 Pt 1 859 866 16611321
   PubMed Web of Science ®Google Scholar
• Vos K Thurlings RM Wijbrandts CA van Schaardenburg D Gerlag DM Tak PP Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis Arthritis Rheum 2007 56 3 772 778 17328049
   PubMed Web of Science ®Google Scholar
• Leandro MJ Cooper N Cambridge G Ehrenstein MR Edwards JC Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology (Oxford) 2007 46 1 29 36 16735454
   PubMed Web of Science ®Google Scholar
• Roll P Palanichamy A Kneitz C Dorner T Tony HP Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis Arthritis Rheum 2006 54 8 2377 2386 16869000
   PubMed Web of Science ®Google Scholar
• Vital EM Rawstron AC Dass S Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion Arthritis Rheum 2011 63 3 603 608 21360489
   PubMed Web of Science ®Google Scholar
• Thurlings RM Vos K Wijbrandts CA Zwinderman AH Gerlag DM Tak PP Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response Ann Rheum Dis 2008 67 7 917 925 17965121
   PubMed Web of Science ®Google Scholar
• Gottenberg JE Ravaud P Bardin T AutoImmunity and Rituximab registry and French Society of Rheumatology Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry Arthritis Rheum 2010 62 9 2625 2632 20506353
   PubMed Web of Science ®Google Scholar
• Edwards JC Cambridge G Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 2001 40 2 205 211 11257159
   PubMed Web of Science ®Google Scholar
• De Vita S Zaja F Sacco S De Candia A Fanin R Ferraccioli G Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells Arthritis Rheum 2002 46 8 2029 2033 12209504
   PubMed Web of Science ®Google Scholar
• Kneitz C Wilhelm M Tony HP Improvement of refractory rheumatoid arthritis after depletion of B cells Scand J Rheumatol 2004 33 2 82 86 15163108
   PubMed Web of Science ®Google Scholar
• Edwards JC Szczepanski L Szechinski J Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 2004 350 25 2572 2581 15201414
   PubMed Web of Science ®Google Scholar
• Emery P Fleischmann R Filipowicz-Sosnowska A DANCER Study Group The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 2006 54 5 1390 1400 16649186
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A Tak PP Zerbini C MIRROR Trial Investigators Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) Rheumatology (Oxford) 2010 49 9 1683 1693 20463186
   PubMed Web of Science ®Google Scholar
• Emery P Deodhar A Rigby WF Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)) Ann Rheum Dis 2010 69 9 1629 1635 20488885
   PubMed Web of Science ®Google Scholar
• Cohen SB Emery P Greenwald MW REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 2006 54 9 2793 2806 16947627
   PubMed Web of Science ®Google Scholar
• Mease PJ Cohen S Gaylis NB Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial J Rheumatol 2010 37 5 917 927 20194448
   PubMed Web of Science ®Google Scholar
• Tak PP Rigby WF Rubbert-Roth A IMAGE Investigators Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Ann Rheum Dis 2011 70 1 39 46 20937671
   PubMed Web of Science ®Google Scholar
• Greenwald MW Shergy WJ Kaine JL Sweetser MT Gilder K Linnik MD Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial Arthritis Rheum 2011 63 3 622 632 21360491
   PubMed Web of Science ®Google Scholar
• Cohen SB Keystone E Genovese MC Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate Ann Rheum Dis 2010 69 6 1158 1161 20439295
   PubMed Web of Science ®Google Scholar
• Haraoui B Bokarewa M Kallmeyer I Bykerk VP RESET Investigators Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial J Rheumatol 2011 38 12 2548 2556 21965646
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ Maneiro JR Ruiz J Roselló R Sanmarti R Romero AB MIRAR Study Group Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study Ann Rheum Dis 2012 71 11 1861 1864 22736086
   PubMed Web of Science ®Google Scholar
• Tak PP Rigby W Rubbert-Roth A Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE Ann Rheum Dis 2012 71 3 351 357 22012969
   PubMed Web of Science ®Google Scholar
• Genovese MC Cohen S Moreland L 20000223 Study Group Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum 2004 50 5 1412 1419 15146410
   PubMed Web of Science ®Google Scholar
• Weinblatt M Combe B Covucci A Aranda R Becker JC Keystone E Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study Arthritis Rheum 2006 54 9 2807 2816 16947384
   PubMed Web of Science ®Google Scholar
• Assmann G Pfreundschuh M Voswinkel J Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers Clin Exp Rheumatol 2010 28 1 Suppl 57 81 83 20412708
   PubMed Web of Science ®Google Scholar
• Chandra PA Margulis Y Schiff C Rituximab is useful in the treatment of Felty’s syndrome Am J Ther 2008 15 4 321 322 18645332
   PubMed Web of Science ®Google Scholar
• Iaccheri B Androudi S Bocci EB Gerli R Cagini C Fiore T Rituximab treatment for persistent scleritis associated with rheumatoid arthritis Ocul Immunol Infamm 2010 18 3 223 225
   PubMed Web of Science ®Google Scholar
• Bredemeier M de Oliveira FK Rocha CM Low- versus high-dose rituximab for rheumatoid arthritis: A systematic review and meta-analysis Arthritis Care Res (Hoboken) 2013
   Web of Science ®Google Scholar
• Baker JF Ostergaard M Emery P Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial Ann Rheum Dis 2013
   Google Scholar
• Buch MH Smolen JS Betteridge N Rituximab Consensus Expert Committee Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Ann Rheum Dis 2011 70 6 909 920 21378402
   PubMed Web of Science ®Google Scholar
• Bastian H Zinke S Egerer K Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study J Rheumatol 2010 37 5 1069 1071 20439529
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K Lie E Nasonov E Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration Ann Rheum Dis 2012 71 3 374 377 21972242
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K Lie E Nasonov E Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries Ann Rheum Dis 2011 70 9 1575 1580 21571731
   PubMed Web of Science ®Google Scholar
• Dass S Rawstron AC Vital EM Henshaw K McGonagle D Emery P Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis Arthritis Rheum 2008 58 10 2993 2999 18821683
   PubMed Web of Science ®Google Scholar
• Narvaez J Díaz-Torné C Ruiz JM Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs Clin Exp Rheumatol 2011 29 6 991 997 22133052
   PubMed Web of Science ®Google Scholar
• Couderc M Mathieu S Pereira B Glace B Soubrier M Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital Arthritis Care Res (Hoboken) 2013 65 4 648 652 23045227
   PubMed Web of Science ®Google Scholar
• Sellam J Hendel-Chavez H Rouanet S B cell activation biomark-ers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study Arthritis Rheum 2011 63 4 933 938 21225699
   PubMed Web of Science ®Google Scholar
• Lal P Su Z Holweg CT Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment Arthritis Rheum 2011 63 12 3681 3691 22127691
   PubMed Web of Science ®Google Scholar
• Nakou M Katsikas G Sidiropoulos P Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response Arthritis Res Ther 2009 11 4 R131 19715572
   PubMed Web of Science ®Google Scholar
• Leandro MJ Cambridge G Ehrenstein MR Edwards JC Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis Rheum 2006 54 2 613 620 16447239
   PubMed Web of Science ®Google Scholar
• Möller B Aeberli D Eggli S Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis Arthritis Res Ther 2009 11 3 R62 19419560
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A Rouanet S Combe B Fcγ receptor type IIIA polymorphism infuences treatment outcomes in patients with rheumatoid arthritis treated with rituximab Ann Rheum Dis 2012 71 6 875 877 22368231
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A Rouanet S Combe B Association between −871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients Rheumatology (Oxford) 2013 52 4 636 641 23264555
   PubMed Web of Science ®Google Scholar
• Fabris M Quartuccio L Lombardi S The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis Autoimmun Rev 2012 11 5 315 320 20974296
   PubMed Web of Science ®Google Scholar
• Sellam J Rouanet S Hendel-Chavez H Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis Arthritis Rheum 2011 63 12 3692 3701 22127692
   PubMed Web of Science ®Google Scholar
• Sellam J Rouanet S Hendel-Chavez H CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis Arthritis Rheum 2013 65 9 2253 2261 23740460
   PubMed Web of Science ®Google Scholar
• Owczarczyk K Lal P Abbas AR A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis Sci Transl Med 2011 3 101 101ra92
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF Emery P Bingham CO3rd Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials J Rheumatol 2010 37 3 558 567 20110520
   PubMed Web of Science ®Google Scholar
• Kimby E Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 2005 31 6 456 473 16054760
   PubMed Web of Science ®Google Scholar
• Salliot C Dougados M Gossec L Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials Ann Rheum Dis 2009 68 1 25 32 18203761
   PubMed Web of Science ®Google Scholar
• Curtis JR Xie F Chen L The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents Ann Rheum Dis 2011 70 8 1401 1406 21586439
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF Emery P Bingham CO Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Ann Rheum Dis 2013 72 9 1496 1502 23136242
   PubMed Web of Science ®Google Scholar
• Keystone E Fleischmann R Emery P Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis Arthritis Rheum 2007 56 12 3896 3908 18050221
   PubMed Web of Science ®Google Scholar
• Casulo C Maragulia J Zelenetz AD Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections Clin Lymphoma Myeloma Leuk 2013 13 2 106 111 23276889
   PubMed Web of Science ®Google Scholar
• Otremba MD Adam SI Price CC Hohuan D Kveton JF Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia Am J Otolaryngol 2012 33 5 619 622 22361345
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou A Douma S Vassiliadis T Chatzimichailidou S Triantafyllou A Aslanidis S Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis Rheumatol Int 2011 31 3 403 404 19830433
   PubMed Web of Science ®Google Scholar
• Gigi E Georgiou T Mougiou D Boura P Raptopoulou-Gigi M Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab Hippokratia 2013 17 1 91 93 23935355
   PubMed Web of Science ®Google Scholar
• Ghrénassia E Mékinian A Rouaghe S Ganne N Fain O Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis Joint Bone Spine 2012 79 1 100 101 21944979
   PubMed Web of Science ®Google Scholar
• Chen YM Chen HH Lai KL Hung WT Lan JL Chen DY The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection Rheumatology (Oxford) 2013 52 4 697 704 23264552
   PubMed Web of Science ®Google Scholar
• Gheuens S Wüthrich C Koralnik IJ Progressive multifocal leukoencephalopathy: why gray and white matter Annu Rev Pathol 2013 8 189 215 23092189
   PubMed Web of Science ®Google Scholar
• Gheuens S Pierone G Peeters P Koralnik IJ Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression J Neurol Neurosurg Psychiatry 2010 81 3 247 254 19828476
   PubMed Web of Science ®Google Scholar
• Clifford DB Ances B Costello C Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis Arch Neurol 2011 68 9 1156 1164 21555606
   PubMed Web of Science ®Google Scholar
• Fleischmann RM Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis Arthritis Rheum 2009 60 11 3225 3228 19877057
   PubMed Web of Science ®Google Scholar
• Bharat A Xie F Baddley JW Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases Arthritis Care Res (Hoboken) 2012 64 4 612 615 22162369
   PubMed Web of Science ®Google Scholar
• Arkema EV van Vollenhoven RF Askling J ARTIS Study Group Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study Ann Rheum Dis 2012 71 11 1865 1867 22739991
   PubMed Web of Science ®Google Scholar
• Sugauchi F Tanaka Y Kusumoto S Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy J Med Virol 2011 83 3 412 418 21264861
   PubMed Web of Science ®Google Scholar
• Fukushima N Mizuta T Tanaka M Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier Ann Oncol 2009 20 12 2013 2017 19561036
   PubMed Web of Science ®Google Scholar
• Hsu C Tsou HH Lin SJ Taiwan Cooperative Oncology Group Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study Hepatology 2013
   Google Scholar
• Ennishi D Yokoyama M Terui Y Does rituximab really induce hepatitis C virus reactivation? J Clin Oncol 2008 26 28 4695 4696 author reply 4696 18824720
   PubMed Web of Science ®Google Scholar
• Dizdar O Tapan U Aksoy S Harputluoglu H Kilickap S Barista I Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C Eur J Haematol 2008 80 5 381 385 18221389
   PubMed Web of Science ®Google Scholar
• Sagnelli E Pisaturo M Sagnelli C Coppola N Rituximab-based treatment, HCV replication, and hepatic flares Clin Dev Immunol 2012 2012 945950 22919406
   PubMedGoogle Scholar
• Oren S Mandelboim M Braun-Moscovici Y Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response Ann Rheum Dis 2008 67 7 937 941 17981914
   PubMed Web of Science ®Google Scholar
• van Assen S Holvast A Benne CA Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab Arthritis Rheum 2010 62 1 75 81 20039396
   PubMed Web of Science ®Google Scholar
• Rehnberg M Brisslert M Amu S Zendjanchi K Håwi G Bokarewa MI Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment Arthritis Res Ther 2010 12 3 R111 20529331
   PubMed Web of Science ®Google Scholar
• Arad U Tzadok S Amir S The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab Vaccine 2011 29 8 1643 1648 21211590
   PubMed Web of Science ®Google Scholar
• Bingham CO3rd Looney RJ Deodhar A Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial Arthritis Rheum 2010 62 1 64 74 20039397
   PubMed Web of Science ®Google Scholar
• Ho LY Mok CC To CH Anselm M Cheung MY Yu KL Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study Open Rheumatol J 2007 1 1 4 19088893
   PubMedGoogle Scholar
• Mok CC Ho LY To CH Rituximab for refractory polymyositis: an open-label prospective study J Rheumatol 2007 34 9 1864 1868 17722224
   PubMed Web of Science ®Google Scholar
• Li EK Tam LS Zhu TY Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 2009 48 8 892 898 19478041
   PubMed Web of Science ®Google Scholar
• Wu B Wilson A Wang FF Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china PLoS One 2012 7 10 e47373 23056637
   PubMed Web of Science ®Google Scholar
• Mok CC Kwan C Chan KY Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: data from the Hong Kong Biologics Registry. [abstract] Arthritis Rheum 2012 64 Suppl 10 388
   Google Scholar
• Mok CC Chan KY Lee KL Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry Int J Rheum Dis 2013 [in press]
   Web of Science ®Google Scholar